

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
HANMI PHARM. CO., LTD.	01/24/2011
RECEIVING PARTY DATA	
Name:	HANMI HOLDINGS CO., LTD.
Street Address:	#45, Bangi-dong, Songpa-gu
City:	Seoul
State/Country:	REPUBLIC OF KOREA
Postal Code:	138-828
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	12425499
Application Number:	12914032
CORRESPONDENCE DATA	
Fax Number:	(202)293-7860
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	202-293-7060
Email:	ADEHART@SUGHRUE.COM
Correspondent Name:	SUGHRUE MION, PLLC
Address Line 1:	2100 PENNSYLVANIA AVE., N.W.
Address Line 2:	SUITE 800
Address Line 4:	WASHINGTON, DISTRICT OF COLUMBIA 20037
ATTORNEY DOCKET NUMBER:	047610
NAME OF SUBMITTER:	Ashley DeHart
Total Attachments: 1 source=047610_Assignment_Applications_Executed#page1.tif	

OP \$80.00 12425499

501443642

PATENT
REEL: 025835 FRAME: 0319

Assignment

Whereas, We, **HANMI PHARM. CO., LTD.**, a Korean corporation, having a place of business at 893-5 Hajeo-Ri, Paltan-Myeon, Hwaseong-Si, Gyeonggi-Do, Republic of Korea, hereinafter called Assignor, is the owner of record of the U.S. Patent Application Nos. 12/425,499 (Reel/Frame No.: 017688/0128; Attorney Docket: Q113155) and 12/914,032 (Reel/Frame No.: 017688/0128; Attorney Docket: Q121489); and

Whereas **HANMI HOLDINGS CO., LTD.** of #45, Bangi-dong, Songpa-gu, Seoul 138-828, Republic of Korea, desires to acquire the right, title, and interest owned by the Assignor in the aforesaid U.S. Patent Applications, and any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged;

HANMI PHARM. CO., LTD., hereby assigns and transfers to **HANMI HOLDINGS CO., LTD.**, their successor, and assigns its right, title and interest in the aforesaid U.S. Patent Applications and the inventions disclosed therein for the United States of America, including all divisions, and continuations thereof, and all Letters Patent of the United States that may be granted thereon, and all reissues thereof, including the right to claim priority under 35 U.S.C. §119; and we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States applications when called upon to do so by the assignee.

IN WITNESS WHEREOF, **HANMI PHARM. CO., LTD.** has executed this Assignment by proper persons duly authorized.

HANMI PHARM. CO., LTD.



Date: January 24, 2011

Name: Gwan Sun LEE

Title: CEO of **HANMI PHARM. CO., LTD.**

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)